FDA Demands Vision Risk Warning on Ozempic and Mounjaro Labels

FDA requires new warnings on medications like Ozempic and Mounjaro due to a rare risk of vision loss. Understand what has changed on the labels and what the symptoms are.

FDA Demands Vision Risk Warning on Ozempic and Mounjaro Labels

TL;DR

  • The FDA is requiring warnings about Non-arteritic anterior ischemic optic neuropathy (NAION) on Ozempic and Mounjaro labels.
  • NAION is a rare eye condition that can cause sudden, painless vision loss due to interrupted blood flow to the optic nerve.
  • The FDA's decision is based on clinical trial data showing a slightly higher incidence of NAION in users of these drugs compared to non-users.
  • The warning applies to GLP-1 agonists including Ozempic, Wegovy, Mounjaro, and Zepbound.
  • Brazil's Anvisa has already mandated similar warnings for semaglutide-based drugs.
  • Patients are advised not to stop medication without consulting their doctor, but to seek immediate medical attention for any sudden vision changes.